Company intelligence

Sling Therapeutics

Biotech

Recent changes

  1. Sep 16, 2026Raised $123M Series C BioSpace
  2. Sep 16, 2026New investor: Sectoral Asset Management BioSpace

Funding History

1 event · sources dated per row
DateEventAmountValuationInvestorsSource
Sep 16, 2026Series C$123M—
Sectoral Asset ManagementTPG Life Sciences InnovationsPhase 3 development of linsitinib
Pulse story

Investors

Sectoral Asset Management

Latest Pulse

  1. Sling Banks $123M To Push Oral Thyroid Eye Disease PillSling Therapeutics closed a $123 million Series C led by Forbion to fund a Phase 3 trial of linsitinib, an oral pill positioned as a more convenient alternative to injectable treatments for thyroid eye disease.→

Coverage Timeline

newest first
  1. FUNDINGSling Banks $123M To Push Oral Thyroid Eye Disease Pill→

All Coverage

FUNDING

Sling Banks $123M To Push Oral Thyroid Eye Disease Pill

Related Companies

Same sector
Scribe TherapeuticsApnimedAttovia TherapeuticsBraveheart BioADARx PharmaceuticalsElectra Therapeutics

Sling Therapeutics FAQ

Who are Sling Therapeutics's investors?

Sling Therapeutics's investors include Sectoral Asset Management.

Sources & methodologyshow
Where these figures come from

Figures are labelled Reported (a source states it), Estimated, Derived (computed from other facts) or Rumored (in talks / unconfirmed). Rumors never replace a confirmed figure. Each figure keeps its own as-of date; history is preserved rather than overwritten.

How we verify data · Suggest a correction